Biocon rolls out generic Afinitor

Biocon is introducing Everolimus tablets,

The medication is the generic of Novartis’ Afinitor.

Everolimus tablets are available in dosage strengths of 2.5 mg, 5 mg, 7.5 mg and 10 mg, with the 10 mg tablet being a ‘day-1’ generic launch.

The product, used to treat certain types of cancers and tumors, is the commercial launch of Everolimus and follows the Food and Drug Administration’s approval in February 2021.

[Read more: Mylan, Biocon receive FDA nod for 'follow-on' insulin glargine Semglee]

“The launch of Everolimus tablets is another important addition to our generics portfolio and underscores our commitment to bringing complex, vertically integrated and affordable generic formulations to the market expeditiously,” said Siddharth Mittal, CEO and managing director. “We will continue our focus on innovation and enhancing capacities to launch new products that make affordable healthcare accessible to millions of patients the world over.”

The company said that the Everolimus launch is further assertion of Biocon’s strategy to focus on vertically integrated, complex Finished Dosage Formulations in niche therapeutic areas, using in-house API capabilities.

[Read more: FDA clears interchangeable insulin biosimilar Semglee]

Everolimus tablets have a market value of approximately $675 million in the 12 months ending July 2021, according to IQVIA.